Title
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2)
UMMS Affiliation
Department of Medicine
Publication Date
2021-02-09
Document Type
Article
Disciplines
Health Services Administration | Health Services Research | Infectious Disease | Internal Medicine | Patient Safety | Therapeutics | Virus Diseases
Abstract
Practice points for clinicians developed by the American College of Physicians addressing these questions: What are the effectiveness and harms of remdesivir in hospitalized patients with coronavirus disease 2019 (COVID-19)? Do effectiveness and harms in hospitalized patients with COVID-19 vary by symptom duration, disease severity, and treatment duration?
Keywords
remdesivir, hospitalized patients, coronavirus disease 2019, COVID-19, effectiveness, harms
DOI of Published Version
10.7326/M20-8101
Source
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 Feb 9. doi: 10.7326/M20-8101. Epub ahead of print. PMID: 33560862. Link to article on publisher's site
Journal/Book/Conference Title
Annals of internal medicine
Related Resources
PubMed ID
33560862
Repository Citation
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. (2021). Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). COVID-19 Publications by UMMS Authors. https://doi.org/10.7326/M20-8101. Retrieved from https://escholarship.umassmed.edu/covid19/178